The pharmaceutical community is abuzz about Retatrutide 120 , a dual-action medication showing remarkable outcomes in early research. This groundbreaking compound, a glucagon-like peptide-1 receptor agonist alongside a GIP compound, appears to substantially reduce body weight and enhance metabolic function . Researchers are proposing that it may of